Navigation Links
Paul Keim Appointed to febit's Scientific Advisory Board

Paul Keim brings deep knowledge in the field of medical microbiology, biodefense and pathogens to febit, the leader in microfluidic microarray DNA analysis technologies

LEXINGTON, Mass. and HEIDELBERG, Germany, April 14 /PRNewswire/ -- febit today announced the recruitment of Paul Keim, Ph.D., for its Scientific Advisory Board. Dr. Keim is Senior Investigator and Director of the Pathogen Genomics Division at TGen (The Translational Genomics Research Institute) in Phoenix, Ariz., and Regents Prof. of Biology at the Northern Arizona University. As an expert in the field of medical microbiology, biosecurity and the genomics of pathogens he brings deep knowledge from these fields to febit.

Dr. Keim's expertise will be particularly helpful in febit's research activities in the field of biosecurity which have resulted from its partnership with In-Q-Tel, the independent strategic investment firm that identifies innovative technology solutions to support the mission of the broader U.S. Intelligence Community. In addition with Dr. Keim's focus on genomic analysis of bacterial pathogens he is an interesting partner in developing special applications in this field for febit's new sequence capture method, HybSelect which enables focused re-sequencing with next-generation sequencers on a high level in output and automation.

Paul Keim will enrich febit's Scientific Advisory Board which consists of leading authorities at the forefront of genetics and genomics research. The SAB members -- from top research institutions and companies -- will provide expert advice on febit's research and development activities associated with its portfolio development.

About febit

febit develops, produces and markets flexible automated solutions for enabling biochip applications in Life Sciences. febit's product portfolio includes various instruments, optimized assays and bioanalytical services, complemented by bioinformatics software and consulting.

For its main applications -- HybSelect, febit's innovative DNA capture method for Next-Generation-Sequencing and protein-coding or non-coding transcriptome profiling -- the highly advanced microfluidics of the patented Geniom Biochip offers the highest degree of automation, flexibility and efficiency available.

For more information please visit:


    febit group, Eva Sterzel,, +49 (0)6221 6510-300

    Russo Partners, Martina Schwarzkopf,, +1 212 845-4292

SOURCE febit
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Michael Troullis Appointed Chief Financial Officer of Quintiles Transnational Corp.
2. Dennis L. Smith Appointed Executive Chairman to Board of Directors of Solstice Neurosciences, Inc.
3. John Marshall and Kevin McGuinness Appointed to Ellex Board
4. Dr. David Sidransky Appointed Chairman of Champions Biotechnology, Inc.
5. David Mott Appointed Non Executive Director at Shire
6. Lucid Expands Support Internationally: Dr. Colin Stahel appointed Director for Asia Pacific Region
7. Dr. Joseph L. Corriveau Appointed Director of Research and Technology
8. Dennis L. Smith Appointed President and Chief Executive Officer of Solstice Neurosciences, Inc.
9. Newly Appointed Dilon Technologies President & CEO Robert G. Moussa Sees BSGI as ... Major Weapon in the Battle Against Cancer
10. Chris Tihansky Appointed President of In Vivo Cellular Imaging Leader Cellvizio Inc.
11. Mr. Richard Decker Appointed Technical Director of Edgewood Chemical Biological Center
Post Your Comments:
(Date:11/24/2015)... Switzerland (PRWEB) , ... November 24, 2015 , ... ... plant and the environment are paramount. Insertion points for in-line sensors can represent ... has developed the InTrac 781/784 series of retractable sensor housings , which ...
(Date:11/24/2015)... 24, 2015 /CNW Telbec/ - ProMetic Life Sciences Inc. (TSX: ... Mr. Pierre Laurin , President and Chief Executive Officer ... upcoming Piper Jaffray 27 th Annual Healthcare Conference to ... 1-2, 2015. st , at 8.50am (ET) ... throughout the day. The presentation will be available live via ...
(Date:11/24/2015)... 2015  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ) ... president and chief executive officer, will present at the 27 ... New York City . The presentation will ... 2015 at 9:30 a.m. EST. and ... at least 15 minutes prior to the presentation to allow ...
(Date:11/24/2015)... Nov. 24, 2015 According to two new studies, ... This is something that many doctors, scientists, and public health ... remains: with fewer PSA tests being done, will there be ... Dr. David Samadi, "Despite the efforts made in ... the second leading cancer cause of death in men, killing ...
Breaking Biology Technology:
(Date:11/16/2015)... , Nov 16, 2015  Synaptics Inc. ... human interface solutions, today announced expansion of its ... ™ touch controller and display driver integration ... of smartphones. These new TDDI products add to ... (HD resolution), TD4302 (WQHD resolution), and TD4322 (FHD ...
(Date:11/10/2015)... Nov. 10, 2015  In this report, ... basis of product, type, application, disease indication, ... this report are consumables, services, software. The ... safety biomarkers, efficacy biomarkers, and validation biomarkers. ... are diagnostics development, drug discovery and development, ...
(Date:11/2/2015)... Nov. 2, 2015  SRI International has been awarded ... preclinical development services to the National Cancer Institute (NCI) ... provide scientific expertise, modern testing and support facilities, and ... pharmacology and toxicology studies to evaluate potential cancer prevention ... The PREVENT Cancer Drug Development Program is an NCI-supported ...
Breaking Biology News(10 mins):